EUVIMEDEUVIMED entdecken
Systematische ÜbersichtFallberichtOpen Access · CC BY-NC-ND 4.0

Does adding hydroxychloroquine to empiric treatment improve the live birth rate in refractory obstetrical antiphospholipid syndrome? A systematic review

Allyssa Hooper, Vanessa Bacal iD, Mohamed A Bedaiwy

American Journal of Reproductive Immunology · 2023

DOI: 10.1111/aji.13761 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift American Journal of Reproductive Immunology, 2023. Verfasst von Allyssa Hooper und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Antiphospholipid Syndrome, Abortion, Spontaneous. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Problem The current standard prevention of obstetric complications in patients with antiphospholipid antibody syndrome (APS) is the use of combination low‐dose aspirin and low molecular weight heparin. However, 20‐30% of women still experience refractory obstetrical APS. Hydroxychloroquine (HCQ) is an immunomodulatory agent that has been shown in laboratory studies to decrease thrombosis risk, support placentation, and minimize the destructive effects of antiphospholipid antibodies. The objective of this study was to evaluate the risk of pregnancy loss upon treatment with HCQ among women with refractory obstetrical APS. Method of study A systematic review was conducted according to PRISMA guidelines. Studies that evaluated the use of HCQ during pregnancy in women with primary APS were included. The primary outcomes of interest were live birth and pregnancy losses after treatment with HCQ.

Results

Twelve studies met inclusion criteria. Three retrospective cohort studies demonstrated improved live birth rate, and four studies demonstrated a reduction in pregnancy loss rate. Two case reports also demonstrated a benefit in the use of HCQ compared to previous obstetrical outcomes.

Conclusions

Our findings suggest a significant benefit of HCQ in addition to aspirin and heparin for patients with APS to mitigate the risk of antiphospholipid antibody mediated obstetrical complications. Randomized controlled trials with standardized patient selection criteria need to be conducted to corroborate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiphospholipid SyndromeAbortion, SpontaneousPregnancyHumansFemaleBirth RateHydroxychloroquineRetrospective StudiesAntibodies, AntiphospholipidAspirin

Stichwörter der Autor:innen

antiphospholipid antibody syndromehydroxychloroquinemiscarriagerecurrent pregnancy losssystematic review

Substanzen

HydroxychloroquineAntibodies, AntiphospholipidAspirin

Autor:innen und Institutionen

  • Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada.
  • Department of Obstetrics & Gynaecology, The University of Toronto, Toronto, Ontario, Canada.
  • Mount Sinai Fertility, Toronto, Ontario, Canada.
  • Department of Obstetrics & Gynecology, The University of British Columbia, Vancouver, British Columbia, Canada.

ORCID-Profile: Vanessa Bacal

Zitieren

APA

Hooper, A., Bacal, V., & Bedaiwy, M. A. (2023). Does adding hydroxychloroquine to empiric treatment improve the live birth rate in refractory obstetrical antiphospholipid syndrome? A systematic review. American Journal of Reproductive Immunology. https://doi.org/10.1111/aji.13761

Vancouver

Hooper A, Bacal V, Bedaiwy MA. Does adding hydroxychloroquine to empiric treatment improve the live birth rate in refractory obstetrical antiphospholipid syndrome? A systematic review. American Journal of Reproductive Immunology. 2023. doi:10.1111/aji.13761

BibTeX
@article{Hooper2023,
  author = {Hooper, Allyssa and Bacal, Vanessa and Bedaiwy, Mohamed A},
  title = {Does adding hydroxychloroquine to empiric treatment improve the live birth rate in refractory obstetrical antiphospholipid syndrome? A systematic review},
  journal = {American Journal of Reproductive Immunology},
  year = {2023},
  doi = {10.1111/aji.13761}
}
Kostenlos starten →